Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheuminations: Can We Now Control the Wolf?

Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS  |  June 1, 2025

Lupus has always had a reputation for being a wild, unrestrained and enigmatic entity. In fact, the very name lupus comes from the Latin word for wolf, a gift from our Roman predecessors who saw a resemblance between lupus rashes and a wolf’s bite. Given the limitations of immunology back then, it is an incredibly fitting term. But things are changing, and the metaphor of this unstoppable, utterly ferocious creature seems to finally be breaking down. Perhaps the best example of this is how we are finally learning to domesticate lupus nephritis. How so? Well, let’s rheuminate!

I salute our clinical mentors who tried their absolute best to tame lupus with whatever tools they could find, such as high-dose corticosteroids, cytotoxic agents and potent immunomodulators. Without a doubt, these treatments work, but they come at a price. We can muzzle the wolf for a while, but, even for the fortunate, the return of lupus from remission is always a looming threat.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

That’s not even taking into account medication side effects, co-morbidity and multimorbidity, and the threat of ongoing kidney damage, such as arteriosclerosis. It is safe to say that we have been able to manage the disease, but we have felt uneasy in maintaining control. That’s what makes this moment in lupus nephritis so remarkable. After decades of hard-fought progress, we are finally beginning to see the wolf respond to a gentler leash. Targeted therapies, such as belimumab and voclosporin, offer new options, not just for suppressing inflammation, but for preserving renal function with greater precision. Newer medications, such as dapirolizumab and obinutuzumab, are showing promising results in clinical trials. These treatments help reshape the behavior of the beast, allowing us to guide the wolf rather than to wrestle it.

We’re also getting smarter about how we understand lupus nephritis. Urine biomarkers, molecular profiling and better disease activity measures are giving us clearer signals about when the wolf is growling. These options can provide supplementary information to the more invasive kidney biopsy. Additionally, newer understanding of autoantibody patterns is providing better clarity about prognosis and disease activity.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Of course, no metaphor is perfect. Lupus will always retain some of its wildness. It doesn’t follow rules, and it certainly doesn’t respond the same way in every patient. Similarly, wolves are not our implacable enemies, but rather are important guardians of our ecosystems, and, as much as I love dogs, not all of them are predictable, affectionate furry bundles of love. Nevertheless, I look forward to seeing the day that we teach our medical students that the disease our Roman forebearers likened to a fearsome wolf has become a known entity, which still requires respect and attention, but is closer to a chihuahua than a dire wolf.


Dr. Kumar

Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS, is the director of the rheumatology fellowship training program at the University of Iowa, Iowa City, and the physician editor of The Rheumatologist. Follow him on X (formerly Twitter) @BharatKumarMD.

Share: 

Filed under:ConditionsOpinionRheuminationsRheuminationsSystemic Lupus Erythematosus Tagged with:kidney diseaseLupus nephritisLupus nephritis supplement

Related Articles

    TNF Blockade for SLE

    September 1, 2010

    Reckless approach versus missed opportunity?

    Tacrolimus Use for Lupus Nephritis Raises Debate over Role in North American Population

    October 10, 2016

    The following summary regarding use of tacrolimus (TAC) in lupus nephritis highlights a number of debatable points. Although the role of TAC in lupus nephritis remains unproved for North American populations, it might be an excellent option in some clinical situations. These situations include lupus flare during pregnancy and also for lupus nephritis when the…

    Kidney Biopsy in Lupus Nephritis

    June 17, 2024

    SAN DIEGO—As part of a Nov. 14 session on lupus nephritis at ACR Convergence 2023, Simone Appenzeller, MD, PhD, shared perspectives on the importance of biopsy to inform its diagnosis, prognosis and treatment, with an emphasis on childhood disease. Prompt diagnosis and treatment of lupus nephritis is perhaps even more important for children than for…

    A Case of Lupus Podocytopathy

    June 17, 2024

    Kidney involvement is a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). Collectively termed lupus nephritis, SLE with kidney involvement comes in many subtypes. The current classification by the International Society of Nephrology/Renal Pathology Society (ISN/RPS), however, does not include lupus podocytopathy, which, through various clinical and epidemiologic studies, has recently been…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences